BLOG

Finsmes

Teclison Closes $5.9M Funding Round

Teclison, a Princeton, NJ-based clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, closed a $5.9m funding round.